Headquartered in Milford, Massachusetts, Waters Corporation (WAT) is a global leader in analytical instruments and laboratory solutions. Valued at a market capitalization of $22.2 billion, the company specializes in liquid chromatography (LC), mass spectrometry (MS), and thermal analysis technologies, serving industries such as pharmaceuticals, life sciences, food safety, environmental testing, and material science.
Companies worth more than $10 billion are commonly referred to as “large caps,” with water perfectly fitting its description, market capitalization exceeding this mark, highlighting its size, influence and advantage in the diagnostic and research industry.
Active Investors: Free newsletter behind the hottest stock headlines to uncover new trade ideas
Its cutting-edge equipment and software enables accurate chemical analysis and molecular detection, playing an important role in drug development, quality control and scientific research. With an emphasis on innovation, sustainability and data-driven insights, Waters Corporation continues to expand its global footprint and increase laboratory efficiency through advanced analytic solutions and digital transformation initiatives.
Despite its remarkable strength, WAT slipped 13% from $423.56, 13% from the 52-week high achieved on January 10th.
In the long term, WAT stock has fallen 4.8% over the past six months, lagging behind XLV's 10.7% profit over the past six months. However, the stock has risen 7.5% over the past 52 weeks, surpassing the marginal return of XLV over the last year.
WAT has been trading above the 200-day moving average since late July, but below the 50-day moving average since mid-February.
On February 12, WAT shares closed more than 5% after reporting fourth quarter results. The $4.10 adjusted EPS exceeded the $4.02 Wall Street expectations. The company's revenue was $872.7 million, while Wall Street forecast was $857.1 million.
Dr. Udit Batra, president and CEO of Waters Corporation, attributed the strong performance to “Pharma's double-digit growth,” stressing that “instruments and repetitive revenues were both single-digit higher in certain currencies.” He highlighted the company's strategic initiatives and operational execution as key factors for this success. WAT expects a full year adjusted EPS to be between $12.70 and $13.
WAT rivals Agilent Technologies, Inc. (a) suffered a loss of 17.2% over the past 52 weeks, falling 13.6% over the past six months.
Nevertheless, Wall Street analysts are cautious about Watt's outlook. The stock has a consensus “Medium Buy” rating from 18 analysts covering it. The average price target of $405.65 suggests a potential upside of 10.1% from the current price level.
On the date of publication, Kritika Sarmah had no position (directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, see BarChart's disclosure policy.
The views and opinions expressed herein are the views and opinions of the authors and are not necessarily Nasdaq, Inc. It does not reflect the opinions of
